Leerink Swann Starts Jazz Pharmaceuticals (JAZZ) at Outperform; Compelling Risk/Reward
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $244.96 -0.36%
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Leerink Swann initiates coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with an Outperform. PT $60.00.
Analyst, Michael Schmidt, said, "We project 2011-13 EPS CAGR of 16%, higher growth than its peers. However, JAZZ trades at a discount on a forward P/E due to concerns over sustainability of growth of its key products. We see near term appreciation as JAZZ exceeds EPS expectations driven by organic growth, applying its unique high margin business model. Not included in our model are accretive acquisitions which diversify revenues while capitalizing on its existing platform."
For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.
Shares of Jazz Pharmaceuticals closed at $44.64 yesterday.
Analyst, Michael Schmidt, said, "We project 2011-13 EPS CAGR of 16%, higher growth than its peers. However, JAZZ trades at a discount on a forward P/E due to concerns over sustainability of growth of its key products. We see near term appreciation as JAZZ exceeds EPS expectations driven by organic growth, applying its unique high margin business model. Not included in our model are accretive acquisitions which diversify revenues while capitalizing on its existing platform."
For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.
Shares of Jazz Pharmaceuticals closed at $44.64 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jazz Pharmaceuticals (JAZZ) PT Raised to $283 at Morgan Stanley
- UBS Starts Schrodinger (SDGR) at Neutral
- RBC Capital Starts Krystal Biotech (KRYS) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
